Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.